home / stock / amrx / amrx articles
Friday, Amneal Pharmaceuticals Inc (NASDAQ:AMRX) announced a significant agreement valued at over $270 million to settle claims related t...
Friday, Amneal Pharmaceuticals Inc (NASDAQ:AMRX) reported fourth-quarter 2023 revenues of $616.98 million, up 1% Y/Y, missing the co...
PHILADELPHIA, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Amneal Pharmaceuticals, Inc. (NYSE:AMRX) ("Am...
U.S. stocks traded higher Tuesday, with the Nasdaq Composite gaining over 100 points. Here are some big stocks recording gains in the trading sessi...
U.S. stocks traded higher, with the Nasdaq Composite gaining around 50 points on Friday. Here are some big stocks recording gains in Friday's s...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NYSE Market:
Amneal Pharmaceuticals Inc. Class A Website:
Builds on successful U.S. biosimilar partnership of 2 oncology products (RELEUKO ® & FYLNETRA ® ) ADL018 is Kashiv’s lead pipeline biosimilar program, currently in Phase III Kashiv BioSciences, LLC (“Kashiv” or the “Companyȁ...
Builds on U.S. biosimilar portfolio of seven products with three commercial and four in pipeline 8 th biosimilar expands portfolio into allergy treatments, a new therapeutic area Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Companyȁ...
Fourth ESG Report Details Company’s Progress Towards Environmental Sustainability and Contributions Toward Building Healthier Communities as a Leading Provider of Accessible Medicines Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Companyȁ...